Rates of Hepatitis C Coinfection in Patients With HIV

A new analysis suggests there’s a need for frequent testing after the hepatitis C virus (HCV) has been cleared. Data from 3 European countries and the United Kingdom indicate a rise in reinfection of acute HCV among men with HIV who have sex with men (MSM). Moderate cure rates of acute HCV have been reported in the last decade among MSM and also are infected with HIV. However, many who either clear the infection spontaneously or through treatment are la...

High hepatitis C prevalence seen in Amsterdam PrEP study participants

Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline. The HCV prevalence seen was more typical of that seen in HIV-positive gay men rather than the much lower rates seen in HIV-negative men. Presenter Maria Prins said that phylogenetic mapping suggested that the explanation might lie in study partici...

Coinfection with HIV-Hepatitis C Can Increase Cancer Risk

People who have HIV are at higher risk of getting lymphoma, about 100 times greater than the general population, a recent study suggests. Even after they get antiretroviral therapy, people who are HIV positive have a 10-fold higher risk of lymphoma. A new study from Europe found that having HIV, plus a hepatitis virus (B, C, or both), further adds to the risk of lymphoma, specifically non-Hodgkin’s lymphoma (NHL). But in a puzzling finding, the researc

Health Canada Approves DAKLINZA™ (daclatasvir) for Difficult-to-Treat Hepatitis C Patient Populations

DAKLINZA™ is approved in Canada in combination with other agents for the treatment of chronic hepatitis C Patients with HIV co-infection, advanced cirrhosis and post-liver transplant HCV recurrence MONTREAL, May 24, 2016 /CNW/ - Bristol-Myers Squibb Canada today announced Health Canada's approval of DAKLINZA™ (daclatasvir), in combination with sofosbuvir (with or without ribavirin) for 12 weeks in the treatment of chronic hepatitis C (CHC) in adult patie

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrenceFriday, February 5, 2016 12:47 pm EST--PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza™ (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without r

U.S. FDA approves Gilead’s hepatitis C drug for expanded use

– Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV –– Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis –FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir/sofosbuvir) for expanded use in